Autologous Immune Cell Therapy vs Chemotherapy and Radiotherapy: A Comprehensive Guide for Patients
It’s not just about eliminating the tumor, but also about teaching the body to defend itself.
Free cancer support
A Shift in Cancer Treatment: From Direct Attack to Immune Activation
For decades, cancer treatment has relied primarily on surgery, chemotherapy, radiotherapy, and later, targeted therapy. These methods focus on directly destroying cancer cells through drugs, radiation, or surgical removal. While effective, they can also damage healthy tissues and weaken the immune system.
In recent years, autologous immune cell therapy has emerged as a complementary strategy—not by attacking cancer cells directly, but by empowering the patient’s own immune system to recognize and destroy them. Instead of completely replacing traditional therapies, immune cell therapy is often combined with chemotherapy, radiotherapy, or targeted drugs to enhance treatment outcomes and long-term survival. Research in liver cancer, colorectal cancer, breast cancer, lung cancer, melanoma, and head and neck cancer suggests that this combined approach can improve survival when executed properly under clinical supervision.
Autologous immune cell therapy is a form of personalized treatment. The patient’s own immune cells are collected, activated, multiplied, and reinfused to strengthen immune surveillance and response.
The treatment process generally involves:
- Collecting immune cells through blood draw or leukapheresis
- Culturing and activating the cells in a certified laboratory
- Expanding them into large quantities
- Conducting rigorous safety and quality checks
- Reinfusing the cells back into the patient
With several rounds of reinfusion, some immune cells may develop immune memory, allowing them to respond more quickly and persistently against cancer cells in the future. The primary goal is to support long-term disease control and reduce the chances of relapse and metastasis.
What Is Autologous Immune Cell Therapy and How Does It Work?
How Immune Cell Therapy Differs from Chemotherapy and Radiotherapy
Chemotherapy and radiotherapy are cytotoxic treatments designed to aggressively destroy rapidly dividing cells. This makes them effective against tumors but also causes collateral damage to normal tissues such as bone marrow, hair follicles, and gastrointestinal cells.
Immune cell therapy differs in several key ways:
- Mechanism: instead of directly killing cells, it enhances or restores immune function
- Timeframe: it supports long-term immune monitoring rather than rapid tumor shrinkage
- Goal: not only to treat existing disease but to prevent recurrence
For many patients, this distinction is essential. Autologous therapy is not an instant “tumor-shrinking cure,” but a strategy aimed at strengthening immune defense before, during, or after standard treatment.
Common Types of Immune Cell Therapies: Different “Units” in the Immune Army
The human immune system includes many kinds of cells, and several can be adapted into therapeutic tools. Major types include:
- NK (Natural Killer) cells
- CIK (Cytokine-Induced Killer) cells
- γδ T cells
- DC (Dendritic Cell) vaccines
- TIL (Tumor-Infiltrating Lymphocytes)
- CAR-T (Chimeric Antigen Receptor T cells)
Each plays a different role—some are front-line defenders, others are precision snipers, and some serve as intelligence officers presenting antigens to train immune responses.
NK Cell Therapy: Enhancing Immunity and Quality of Life
Natural killer cells account for approximately 10% of lymphocytes and are the first defenders against cancer and viral infection. Unlike T cells, NK cells do not require antigen presentation. They recognize stress signals on cancer cells and induce apoptosis using perforin and granzyme.
Advantages:
- Generally well tolerated
- Support immunity and reduce infection
- Improve strength and energy
Limitations:
- Limited tumor shrinking when used alone, especially in solid tumors
- More suitable as supportive therapy rather than a curative standalone treatment
For patients, NK therapy may help maintain physical condition, making it easier to tolerate chemotherapy, radiotherapy, or targeted therapy.
CIK Therapy: Broad-Spectrum Killing with the Help of Combination Treatment
CIK cells possess characteristics of both NK and T cells, including the CD3+CD56+ subset known as NKT cells. They can expand rapidly in culture and release cytokines that exert antitumor effects across multiple cancer types.
Strengths:
- Strong cytotoxicity
- Can be expanded into billions of cells
- Demonstrated safety in multiple studies
Challenges:
- Reduced specificity compared to CAR-T
- Tumor microenvironment may suppress activity
- Usually requires combination with chemotherapy, targeted therapy, or checkpoint inhibitors
As a result, CIK therapy is best viewed as a partner therapy rather than a solo treatment.
Dendritic Cell Vaccines: Precision with Antigen Challenges
As the body’s most powerful antigen-presenting cells, dendritic cells prime T cells to recognize tumor antigens. When effective antigens are used, DC vaccines can promote immune memory and prevent recurrence.
Advantages:
- High specificity
- Lower side-effects
Challenges:
- Difficulties in obtaining tumor antigens
- Tumor mutation and heterogeneity complicate antigen selection
- Best results achieved when the correct antigen source is identified
TIL Therapy: Experienced Fighters Recruited from the Tumor Itself
Tumor-infiltrating lymphocytes are extracted from the tumor microenvironment. They already recognize cancer cells, making them powerful tools when expanded and reinfused.
Advantages:
- High specificity and cytotoxicity
- Promising results in melanoma and certain other cancers
Limitations:
- Requires fresh tumor tissue, limiting use
- Manufacturing complexity
- Potential contamination if not handled properly
- Often requires preparatory chemotherapy
Because of its risks and required expertise, TIL therapy should only be performed in accredited hospitals.
CAR-T Therapy: Precision but High Cost and Risk
CAR-T therapy genetically engineers T cells to carry a receptor that identifies specific tumor antigens. It has shown unprecedented success in certain blood cancers.
Strengths:
- High remission rates in refractory leukemia and lymphoma
- Often requires only a single infusion
Risks and limitations:
- Cytokine release syndrome and neurotoxicity
- Off-target effects
- Extremely high cost
- Currently limited efficacy in most solid tumors due to antigen challenges and tumor microenvironment
CAR-T represents a major breakthrough—but remains specialized, expensive, and intensive.
Why Combination Therapy Matters
Evidence shows that most immune cell therapies—except CAR-T—provide the best results when combined with standard treatment.
Examples:
- Chemotherapy and radiotherapy release tumor antigens
- Checkpoint inhibitors lift immune suppression
- Immune cell infusion reinforces long-term monitoring
It is this combination, not substitution, that is key. Patients should view immune therapy as a complementary tool—not a miracle cure that replaces clinical protocols.
Safety, Legitimacy, and Patient Awareness
Immune cell therapy requires strict regulation and quality control. Cells must be collected, cultured, tested, and reinfused under certified sterile conditions.
Patients should be cautious of:
- Private clinics offering unapproved therapies
- Claims of “no side effects” or “100% cure”
- Treatments not accompanied by standard oncology care
Accredited hospitals and certified laboratories are essential for safety. Consulting with experienced oncologists is crucial before pursuing immune cell therapy.
Patient-Centered Conclusion: A Hopeful Tool, Not a Myth
Autologous immune cell therapy represents progress—not magic. Its value lies in:
- Supporting immune recovery and surveillance
- Reducing recurrence risk
- Enhancing the effects of standard therapies
- Potentially improving quality of life
It is not suited for every patient or every tumor type, nor should it be viewed as a replacement for chemotherapy or radiotherapy. Instead, it offers an additional layer of defense within a personalized treatment plan. Working with qualified specialists, patients can determine whether immune cell therapy plays a meaningful role in their cancer journey.
Want to know how to choose the most suitable adjuvant therapy for cancer?
Contact our professional team now
References
- Borrego, F. (2016). Editorial: NK cell-based cancer immunotherapy. Frontiers in Immunology, 7, 249. https://doi.org/10.3389/fimmu.2016.00249 Frontiers
- Shevtsov, M., & Multhoff, G. (2016). Immunological and translational aspects of NK cell-based antitumor immunotherapies. Frontiers in Immunology, 7, 492. https://doi.org/10.3389/fimmu.2016.00492 Frontiers
- Guo, Y., et al. (2015). Cytokine-induced killer (CIK) cells: From basic research to clinical translation. OncoTargets and Therapy, 8, 2195–2206. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4593361/ PMC
- Garofano, F., et al. (2019). Clinical trials with combination of cytokine-induced killer cells and chemotherapy in solid tumors. International Journal of Molecular Sciences, 20(17), 4307. https://doi.org/10.3390/ijms20174307 MDPI
- Sánchez-León, M. L., et al. (2022). The effects of dendritic cell-based vaccines in the tumor microenvironment. Frontiers in Immunology, 13, 1050484. https://doi.org/10.3389/fimmu.2022.1050484 Frontiers
- Rosenberg, S. A., & Restifo, N. P. (2009). Adoptive cell therapy for the treatment of patients with metastatic melanoma. Critical Reviews in Oncogenesis, 14(3), 217–228. https://doi.org/10.1615/CritRevOncog.v14.i3.40 PubMed+1
- Grupp, S. A., et al. (2013). Chimeric antigen receptor–modified T cells for acute lymphoid leukemia. New England Journal of Medicine, 368(16), 1509–1518. https://doi.org/10.1056/NEJMoa1215134 New England Journal of Medicine+1
- Maude, S. L., et al. (2014). Chimeric antigen receptor T cells for sustained remissions in leukemia. New England Journal of Medicine, 371(16), 1507–1517. https://doi.org/10.1056/NEJMoa1407222 New England Journal of Medicine
- Frey, N. V., et al. (2019). Chimeric antigen receptor T cells for acute lymphoblastic leukemia. American Journal of Hematology, 94(7), S24–S27. https://doi.org/10.1002/ajh.25442 Wiley Online Library
- Jiang, Y., et al. (2025). Current status of cytokine-induced killer cells and their combination strategies in cancer therapy. Frontiers in Immunology, 16, 1476644. https://doi.org/10.3389/fimmu.2025.1476644 Frontiers
- National Cancer Institute. (2024). Lifileucel first cellular therapy approved for cancer (TIL therapy for melanoma). https://www.cancer.gov/news-events/cancer-currents-blog/2024/fda-amtagvi-til-therapy-melanoma Cancer.gov